Vote!

Advaxis Phase I Survival Update

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed...

read more...

Published By : MedicalNews - Thursday, 29 July

• Older Health Info
• Vote! Topline Results From Phase 3 Trial Of Sunitinib With Erlotinib In Advanced Non-Small Cell Lung Cancer (NSCLC) MedicalNews - Tuesday, 24 August
  • 'Basal-Like' Breast Cancer Does Not Originate From Basal Stem Cells - MedicalNews
  • Inhibitex Successfully Completes Phase 1a Trial Of INX-189 - MedicalNews
  • Macmillan's Response To NICE Decision On Liver Cancer Drug - MedicalNews
• Vote! Advaxis Completes Dosing Vanguard Group In Phase II Cervical Dysplasia (CIN) Study MedicalNews - Friday, 20 August
  • Canine Hip Dysplasia May Be Underreported, According To Penn Vet Comparative Study - MedicalNews
  • Inhibitex Successfully Completes Phase 1a Trial Of INX-189 - MedicalNews
  • Impax Pharmaceuticals Completes Enrollment In ADVANCE-PD Phase III Trial Of IPX066 In Parkinson's Disease - MedicalNews
• Vote! Global Update: Treatments: Drug Schedule Improves Survival Rate of Those With AIDS and Tuberculosis NYT - Health Blog - Monday, 9 August
  • Commitments To Global HIV/AIDS Programs Falter For 'First Time In 15 Years,' UNAIDS Chief Says - MedicalNews
  • Cheap And Accurate Tuberculosis Test Gives Results In Under Two Hours - MedicalNews
  • Roche Provides Update On FDA Application For T-DM1 - MedicalNews